Safety, PK and PD of FLQ-101 in Premature Neonates

Recruiting Phase 1 Interventional Study
Retinopathy of Prematurity (ROP)
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
4 Days – 5 Days
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Prevention
Participants needed
18 (estimated)
Sponsor
FELIQS INC. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Written consent is obtained from parent(s) or legal guardian. * Neonates born at 26 weeks +0 days and 27 weeks +6 days of gestation. * Male or female infants with a birth weight greater than or equal to 650 gm. Exclusion Criteria: * Neonates with congenital malformation of t…
Contacts

Clinical Trial Office

+81-942-707-330

clinicaltrial@feliqs.com

CONTACT